Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Overview of attention for article published in New England Journal of Medicine, September 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news: 40 news outlets
blogs: 3 blogs
policy: 2 policy sources
twitter: 158 X users
patent: 11 patents
facebook: 3 Facebook pages

wikipedia: 4 Wikipedia pages
reddit: 2 Redditors
video: 1 YouTube creator
guideline: 5 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 530 Mendeley

So far, Altmetric has seen 3 posts from 3 blogs.

Ann Robinson’s research reviews—1 October 2021

Latest BMJ blogs, 01 Oct 2021

Ethics of paying people to enrol in…

RCT: Overall survival benefit with Tebentafusp in metastatic uveal melanoma.

SPECIALTIES, 28 Sep 2021

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma – New England Journal of…

Survival Up With Tebentafusp in Metastatic Uveal Melanoma

Physician's Weekly, 23 Sep 2021

THURSDAY, Sept. 23, 2021 (HealthDay News) — For patients with previously untreated metastatic uveal melanoma, treatment with…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.